openPR Logo
Press release

Chronic Obstructive Pulmonary Disease Drugs Market Size, Share & Forecast 2025-2032: Biologics & Inhalation Therapies Driving Growth

09-05-2025 12:10 PM CET | Health & Medicine

Press release from: DataM Intelligence 4market Research LLP

Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

The global Chronic Obstructive Pulmonary Disease (COPD) drugs market was valued at US$ 24.67 billion in 2024 and is projected to reach US$ 35.15 billion by 2032, growing at a compound annual growth rate (CAGR) of 4.9% during the forecast period 2025-2032.

The Chronic Obstructive Pulmonary Disease (COPD) Drugs Market refers to the global industry focused on the research, development, manufacturing, and distribution of pharmaceutical treatments designed to manage COPD, a progressive lung disease that causes airflow obstruction and breathing difficulties. This market includes a range of drug classes such as bronchodilators, corticosteroids, phosphodiesterase-4 inhibitors, combination therapies, and emerging biologics. The goal of these drugs is to reduce symptoms, prevent exacerbations, improve lung function, and enhance patients' quality of life. Growth in this market is driven by the rising prevalence of COPD, increasing approvals of novel therapies, and advancements in inhalation drug delivery technologies.

📌 Access valuable insights with our sample report - (Please enter your Corporate Email ID to get priority access):- https://www.datamintelligence.com/download-sample/chronic-obstructive-pulmonary-disease-drugs-market?rk

Market Overview

Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory condition characterized by persistent airflow limitation and symptoms like breathlessness, chronic cough, and mucus production, primarily caused by smoking or exposure to air pollutants. The main types include chronic bronchitis, marked by airway inflammation and mucus production, and emphysema, involving damage to lung air sacs. Treatments such as bronchodilators, corticosteroids, combination therapies, and novel drugs aim to manage symptoms and improve quality of life. The market is driven by rising COPD prevalence, increasing demand for combination therapies, and advancements in drug delivery systems.

Market Opportunities

Key opportunities include the development of novel therapies like biologics, advancements in inhalation technologies (e.g., soft mist inhalers), and growing healthcare investments in low- and middle-income countries (LMICs) where COPD burden is high. Strategic partnerships and product launches also fuel market expansion.

Key Trends

Shift toward combination therapies for enhanced symptom management.
Introduction of biologics and targeted therapies, such as monoclonal antibodies.
Advancements in inhalation devices improving drug delivery and patient adherence.

Recent Developments

September 2024: GSK announced positive Phase III MATINEE trial results for Nucala (mepolizumab), a monoclonal antibody reducing exacerbations in COPD patients.
September 2024: The FDA approved Dupixent (dupilumab) as the first biologic for adults with inadequately controlled eosinophilic COPD in the U.S.
July 2024: The EMA approved Dupixent as an add-on maintenance treatment for adults with uncontrolled eosinophilic COPD.
June 2024: Verona Pharma's Ohtuvayre (ensifentrine) received FDA approval as the first novel inhaled COPD treatment in over 20 years.
November 2023: Lupin Limited launched Vilfuro-G, the world's first fixed-dose triple combination drug for COPD management in India.

📌 Speak to Our Senior Analyst and Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/chronic-obstructive-pulmonary-disease-drugs-market

Market Dynamics: Drivers

Increasing Prevalence of COPD
The rising prevalence of COPD is a major driver, fueled by smoking, air pollution, and aging populations. According to the World Health Organization (November 2024), COPD is the fourth leading cause of death globally, causing 3.5 million deaths in 2021, with 90% of deaths in individuals under 70 occurring in LMICs. Tobacco smoking accounts for over 70% of cases in high-income countries and 30-40% in LMICs, where household air pollution is a significant risk factor. This growing burden, coupled with product approvals like Dupixent (dupilumab) by the EMA (July 2024) for eosinophilic COPD, drives demand for effective treatments.

Market Dynamics: Restraints

Adverse Effects of Drugs
Adverse effects of COPD medications, such as anticholinergics (e.g., dry mouth, confusion), long-acting beta-agonists (e.g., tremors, increased heart rate), and inhaled corticosteroids (e.g., 41% increased pneumonia risk), reduce patient adherence and impact quality of life. Side effects like oral candidiasis, dysphonia, and roflumilast-related nausea and insomnia further discourage consistent use, limiting market growth.

Market Segment Analysis

By Drug Class: Bronchodilators Dominate
The bronchodilators segment holds the largest market share due to its effectiveness in relieving COPD symptoms by relaxing and widening airways. Types include beta-adrenergic agonists (e.g., albuterol, salmeterol), anticholinergics, and combination therapies. The segment's growth is driven by rising COPD prevalence and innovations like Verona Pharma's Ohtuvayre (ensifentrine), a dual PDE3/PDE4 inhibitor approved by the FDA (June 2024) as the first novel inhaled COPD treatment in over 20 years.

By Route of Administration
Inhalation therapies dominate due to direct lung delivery, with oral and other routes used for specific treatments like antibiotics or roflumilast.

By Distribution Channel
Hospital pharmacies lead due to the need for specialized COPD medications, followed by retail and online pharmacies, which are growing with increased access to treatments.

By Region
North America and Asia-Pacific are key regions, with North America leading due to high COPD prevalence and Asia-Pacific growing rapidly due to rising smoking rates and healthcare investments.

📌 Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=chronic-obstructive-pulmonary-disease-drugs-market

Geographical Share
North America Holds Significant Share
North America accounts for a major share of the COPD drugs market, driven by high COPD prevalence (16 million diagnosed in the U.S.), an aging population, and advanced healthcare infrastructure. Approximately 300,000 U.S. patients with eosinophilic COPD face a 30% higher risk of exacerbations, increasing demand for therapies like Dupixent, approved by the FDA (September 2024) for eosinophilic COPD.

Asia-Pacific Grows Rapidly
Asia-Pacific is the fastest-growing region, driven by high smoking rates, air pollution, and aging populations in countries like China and India. WHO data highlights that over 90% of COPD deaths occur in LMICs, emphasizing the need for treatments. Innovations like Lupin's Vilfuro-G, a triple-combination therapy launched in India (November 2023), further propel market growth.

Major Players
Key companies in the COPD drugs market include:

Boehringer Ingelheim Pharmaceuticals, Inc.
GSK plc
Viatris Inc. (Mylan N.V.)
Lupin Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Ltd.
AstraZeneca
Organon group of companies
Pfizer Inc.
Covis Pharma GmbH

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Chronic Obstructive Pulmonary Disease Drugs Market Size, Share & Forecast 2025-2032: Biologics & Inhalation Therapies Driving Growth here

News-ID: 4171628 • Views: …

More Releases from DataM Intelligence 4market Research LLP

Knee Replacement Surgery Market to Reach USD 16.17 Billion by 2030, Advancing at 6.1% CAGR
Knee Replacement Surgery Market to Reach USD 16.17 Billion by 2030, Advancing at …
Robotic Surgery, 3D Printing, and Outpatient Knee Procedures Spearhead Market Transformation The Global Knee Replacement Surgery Market, valued at USD 12.12 billion in 2025, is projected to surge to USD 16.17 billion by 2030, growing at a CAGR of 6.1% during the forecast period (2025-2030), according to DataM Intelligence. The market is witnessing steady expansion, fueled by rising prevalence of osteoarthritis and rheumatoid arthritis, obesity-related joint degeneration, and the aging global…
Marine Coatings Market to Reach USD 10.20 Billion by 2032, Growing at 6.24% CAGR
Marine Coatings Market to Reach USD 10.20 Billion by 2032, Growing at 6.24% CAGR
Rising Demand for Anti-Corrosion Coatings and Shipbuilding Activities Fuelling Market Expansion The Global Marine Coatings Market, valued at USD 6.28 billion in 2024, is projected to reach USD 10.20 billion by 2032, growing at a CAGR of 6.24% during the forecast period (2025-2032), according to DataM Intelligence. The market's growth is driven by rising shipbuilding activities, increasing offshore oil and gas exploration, and the growing adoption of eco-friendly, anti-corrosion marine coatings.…
Sleep Apnea Devices Market to Reach USD 11.6 Billion by 2032, Growing at 7.6% CAGR
Sleep Apnea Devices Market to Reach USD 11.6 Billion by 2032, Growing at 7.6% CA …
Telemedicine Integration and Home Sleep Testing Technologies Drive Global Market Expansion The Global Sleep Apnea Devices Market, valued at USD 6.4 billion in 2024, is projected to reach USD 11.6 billion by 2032, advancing at a CAGR of 7.6% during the forecast period (2025-2032), according to DataM Intelligence. Growing use of telemedicine, artificial intelligence (AI), and mobile health (mHealth) platforms in diagnostic and therapeutic processes is significantly accelerating market adoption. Advances…
Caustic Soda Market to Reach USD 71.0 Billion by 2033, Driven by Aluminum and Textile Industries
Caustic Soda Market to Reach USD 71.0 Billion by 2033, Driven by Aluminum and Te …
Rising Demand in Automotive, Aerospace, and Water Treatment Sectors Strengthens Global Market Outlook The Global Caustic Soda Market, valued at USD 47.4 billion in 2024, is projected to reach USD 71.0 billion by 2033, growing at a steady CAGR of 4.7% during the forecast period (2025-2033), according to DataM Intelligence. Market growth is primarily driven by surging aluminum production, robust developments in textiles and pulp & paper industries, and the expanding…

All 5 Releases


More Releases for COPD

Copd Drugs Market Size Analysis by Application, Type, and Region: Forecast to Co …
USA, New Jersey- According to Market Research Intellect, the global Copd Drugs market in the Internet, Communication and Technology category is projected to witness significant growth from 2025 to 2032. Market dynamics, technological advancements, and evolving consumer demand are expected to drive expansion during this period. Because respiratory problems are becoming more common worldwide, especially among smokers and older populations, the market for COPD medications is expanding steadily. The need…
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market 2024-2030 Growth: …
Growth: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Insights : For stakeholders, an optimistic view is shown by the thorough study of the worldwide "Chronic Obstructive Pulmonary Disease (COPD) Treatment market". The research provides specifics on the market's historical and present conditions as well as projected trends and size. Decision-makers may navigate the competitive environment and investment possibilities in the Chronic Obstructive Pulmonary Disease (COPD) Treatment market with the use of…
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market - Breathing Sol …
Newark, New Castle, USA - new report, titled Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Obstructive Pulmonary Disease…
Asthma & COPD Drugs Market - Breathe Freely, Live Fully: Empowering Respiratory …
Newark, New Castle, USA - new report, titled Asthma & COPD Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Asthma & COPD Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Asthma & COPD Drugs market. The report offers…
Copd CBD Gummies: Reviews (Shocking Facts) Copd CBD Oil "Ingredients" Pain Relie …
Copd CBD Gummies: With the increasing need for both individual and expert degrees, the stress and also stress are also enhancing. Individuals are using various methods to fight it. However, as a result of much less time for self, it is really hard. Here the natural herbs and supplements have actually discovered their way into our lives. The Copd CBD Oil are instances of super-effective natural supplements. The CBD existing…
Power Harmonica to Cure Chronic Asthma & COPD
Power Harmonica is a free reed wind musical instrument. It is small rectangular shaped musical instrument. It has 48 number of holes which makes it special and different from other harmonica's. It's a pocket-friendly musical instrument. Power Harmonica is used as a natural treatment for many types of lung disorders and has no side effects. To play Power Harmonica there is no need of having a musical background it can be…